|
KMID : 0882420060700060688
|
|
Korean Journal of Medicine
2006 Volume.70 No. 6 p.688 ~ p.694
|
|
|
Carboplatin, ifosfamide, and etoposide chemotherapy for extensive-disease small cell lung cancer
|
|
Ryu Hee-Juang
Kim Young-Nam
Kyung Sun-Yong
Park Se-Hoon
An Chang-Hyeok
Bang Soo-Mi
Lee Sang-Pyo
Lee Jae-Ik
Park Jung-Woong
Cho Eun-Kyung
Jeong Sung-Hwan
Shin Dong-Bok
Lee Jae-Hoon
|
|
|
Abstract
|
|
|
Background : This prospective phase II study assessed the efficacy and toxicity of the combination of carboplatin, ifosfamide and etoposide for previously untreated patients with extensive-disease small cell lung cancer (ED-SCLC).
Methods : Patients with ED-SCLC received a combination chemotherapy with carboplatin AUC 6.0 on day 1, ifosfamide 1200 mg/m2 on day 1-3, and etoposide 100 mg/m2 on day 1-3.
Results : Forty-one patients received a median of six cycles of chemotherapy. A complete response was seen in 5 patients and a partial response was seen in 33 patients (overall response 95%). The median duration of the response was 5.1 months (95% CI; 3.4-6.8 months). The median time to progression and overall survival were 7.4 months (95% CI; 6.1-8.6 months) and 10.7 months (95% CI; 6.9-14.6 months), respectively, providing the one-year survival rate of 43.9%. Grade 3～4 anemia, neutropenia and thrombocytopenia occurred in 14%, 7% and 6% in a total of 212 cycles, respectively. Non-hematologic toxicities were generally mild and manageable. No treatment related death was observed.
Conclusion : The combination chemotherapy of carboplatin, etoposide and ifosfamide showed an effective response rate and acceptable toxicity.(Korean J Med 70:688-694, 2006)
|
|
|
KEYWORD
|
|
|
Ifosfamide, Etoposide, Carboplatin, Small cell lung carcinoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|